$UroGen Pharma Ltd (URGN.US)$ Following Pre-NDA Meeting With...
$UroGen Pharma Ltd(URGN.US$ Following Pre-NDA Meeting With The FDA, UroGen Announces Rolling NDA Submission For UGN-102 For Low-grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer To Begin January 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment